On October 16, 2025, the Schall Law Firm announced a securities fraud investigation into Larimar Therapeutics, citing potential violations of securities laws. The investigation focuses on whether the company issued false or misleading statements or failed to disclose material information to investors.
The investigation follows Larimar’s disclosure on September 29, 2025, of data from an ongoing open‑label study of nomlabofusp in Friedreich’s ataxia patients. The company described the data as "positive" but also reported that seven participants experienced severe allergic reactions or anaphylaxis.
The Schall Law Firm, a national shareholder rights litigation firm, is encouraging shareholders to join the investigation and has provided contact information for interested parties. The firm’s involvement signals a formal legal inquiry into the company’s disclosures and potential compliance with securities regulations.
This regulatory action is significant for Larimar as it may lead to further scrutiny of the company’s clinical data and investor communications, potentially impacting future regulatory approvals and investor confidence.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.